人福医药：奥卡西平缓释片获得美国FDA暂定批准文号

Group 1 - The core point of the article is that Renfu Pharmaceutical has received a tentative approval number from the US FDA for its drug Oxycarbazepine extended-release tablets, which are intended for the treatment of partial seizures in patients aged 6 and older [2] - The company has invested approximately 15 million RMB in the research and development of this drug [2] - Several manufacturers, in addition to the original manufacturer Supernus, have received either formal or tentative approval numbers for this product [2] Group 2 - The product can only be marketed in the US after the original drug's patent expires and the FDA grants final approval [2] - The company has issued a reminder to investors to be aware of investment risks associated with this development [2]